1-20 of 115
Mark J. Levis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Trials & Observations
Sun Loo, Andrew W. Roberts, Natasha S. Anstee, Glen A. Kennedy, Simon He, Anthony P. Schwarer, Anoop K. Enjeti, James D’Rozario, Paula Marlton, Ian A. Bilmon, John Taper, Gavin Cull, Campbell Tiley, Emma Verner, Uwe Hahn, Devendra K. Hiwase, Harry J. Iland, Nick Murphy, Sundra Ramanathan, John Reynolds, Doen Ming Ong, Ing Soo Tiong, Meaghan Wall, Michael Murray, Tristan Rawling, Joanna Leadbetter, Leesa Rowley, Maya Latimer, Sam Yuen, Stephen B. Ting, Chun Yew Fong, Kirk Morris, Ashish Bajel, John F. Seymour, Mark J. Levis, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (23): 1960–1971.
https://doi.org/10.1182/blood.2023020301
Published: 2023
Includes: Supplemental data
Journal Articles

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

Ruiqi Zhu, Courtney Shirley, Haihua Chu, Li Li, Bao Nguyen, Jaesung Seo, Tessa Seale, Amy Duffield, Louis M. Staudt, Mark J. Levis, Yu Hu, Donald Small
Journal: Blood
Blood (2023) 142 (Supplement 1): 5769.
https://doi.org/10.1182/blood-2023-190696
Published: 2023
Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik
Journal: Blood
Blood (2023) 142 (Supplement 1): 3473.
https://doi.org/10.1182/blood-2023-179394
Published: 2023
Journal Articles

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard J. Jones, Anurag K. Singh, Mark R. Litzow, John R. Wingard, Esperanza B. Papadopoulos, Alexander Perl, Robert J. Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K. Waller, Sumithira Vasu, Melhem M. Solh, Asmita Mishra, Lori S. Muffly, Hee-Je Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H. Wei, Guido Marcucci, Nahla Hasabou, Mathew Rosales, Jason Hill, Stanley C. Gill, Rishita Nuthethi, Denise King, Heather Wittsack, Adam Mendizabel, Steven M. Devine, Mary M. Horowitz, Yi-Bin Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 973.
https://doi.org/10.1182/blood-2023-177929
Published: 2023
Journal Articles

Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Companion Diagnostic Development

Jaime E Rohrbach, Ken C N Chang, Maha Karnoub, Li Liu, Yasser Mostafa Kamel, Shirin Khambata-Ford, Shawn Rivera, Jelveh Lameh, Ekaterina Rudenko, Jordan Thornes, Sarah Todt, Jason Gerhold, Ying Huang, Jeffrey E Miller, Alexander Perl, Mark J. Levis, Kazumi Ito
Journal: Blood
Blood (2023) 142 (Supplement 1): 4260.
https://doi.org/10.1182/blood-2023-186658
Published: 2023
Journal Articles

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3 -ITD+ AML Patients (pts)

Alexander Perl, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Heeje Kim, Pavel Zak, Po-Nan Wang, Jaime E Rohrbach, Ken C N Chang, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F Schlenk, Mark J. Levis
Journal: Blood
Blood (2023) 142 (Supplement 1): 832.
https://doi.org/10.1182/blood-2023-186785
Published: 2023
Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Naval Daver, Joshua F. Zeidner, Junichiro Yuda, Justin M. Watts, Mark J. Levis, Kentaro Fukushima, Takayuki Ikezoe, Yoshiaki Ogawa, Joseph Brandwein, Eunice S. Wang, Yasushi Miyazaki, Timothy Pardee, Naoko Hosono, Takahiro Shima, Hisayuki Yokoyama, Noboru Asada, Joseph Jurcic, Hongliang Cai, Akinobu Watanabe, Matthew Hitron, Emily Brooks, Bo Xu, Jatin Shah, Hagop M. Kantarjian, Harry P. Erba
Journal: Blood
Blood (2023) 142 (Supplement 1): 2911.
https://doi.org/10.1182/blood-2023-179252
Published: 2023
Journal Articles

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

Tessa Seale, Li Li, J. Kyle Bruner, Bao Nguyen, Mark J. Levis, Christine Pratilas, Donald Small
Journal: Blood
Blood (2023) 142 (Supplement 1): 2790.
https://doi.org/10.1182/blood-2023-184338
Published: 2023
Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo
Journal: Blood
Blood (2023) 142 (Supplement 1): 3582.
https://doi.org/10.1182/blood-2023-191047
Published: 2023
Journal Articles

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Harry P. Erba, Herve Dombret, Alexander Perl, Tsvetomir Mitov, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Youngsook Choi, Mark J. Levis, Richard F Schlenk
Journal: Blood
Blood (2023) 142 (Supplement 1): 972.
https://doi.org/10.1182/blood-2023-186206
Published: 2023
Journal Articles

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Matthew Scarlotta, Jonathan Webster, Matthew Newman, Cory Schulz, Kristin Stokvis, Alexander J. Ambinder, Tania Jain, William Brian Dalton, Lukasz P. Gondek, Gabrielle T. Prince, Gabriel Ghiaur, Christopher S. Hourigan, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Mark J. Levis
Journal: Blood
Blood (2022) 140 (Supplement 1): 11747–11748.
https://doi.org/10.1182/blood-2022-160300
Published: 2022
Journal Articles

Engaging Continuing Medical Education Reveals Persisting Knowledge and Practice Gaps in FLT3-Positve AML

Katie Robinson, Jillian Scavone Scavone, Emily Scully, Will Cioffi, Robert A. Esgro, Mark J. Levis
Journal: Blood
Blood (2022) 140 (Supplement 1): 13132.
https://doi.org/10.1182/blood-2022-157187
Published: 2022
Journal Articles

Impact of Inotuzumb Ozogamicin on Outcome in Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Sabine Kayser, Chiara Sartor, Fabio Giglio, Alessandro Bruno, Jonathan Webster, Mark J. Levis, Richard F. Schlenk, Cristina Papayannidis
Journal: Blood
Blood (2022) 140 (Supplement 1): 8906–8907.
https://doi.org/10.1182/blood-2022-166193
Published: 2022
Journal Articles

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

James McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen A Strickland, Amir T. Fathi, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Mark J. Levis
Journal: Blood
Blood (2022) 140 (Supplement 1): 3312–3314.
https://doi.org/10.1182/blood-2022-159680
Published: 2022
Journal Articles

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Vanessa E. Kennedy, Cheryl Peretz, Paul Lee, Brenda Chyla, Yan Sun, Monique Dail, Jason Hill, Elaine Tran, Andrew Koh, Jessica K. Altman, Naval Daver, Mark J. Levis, James McCloskey, Alexander Perl, Catherine Smith
Journal: Blood
Blood (2022) 140 (Supplement 1): 2244–2246.
https://doi.org/10.1182/blood-2022-160304
Published: 2022
Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Richard F. Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Aziz Benzohra, Arnaud Lesegretain, Jorge E. Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba
Journal: Blood
Blood (2022) 140 (Supplement 1): 2130–2132.
https://doi.org/10.1182/blood-2022-169011
Published: 2022
Journal Articles

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Mark J. Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Heeje Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken CN Chang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge E. Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander Perl
Journal: Blood
Blood (2022) 140 (Supplement 1): 546–548.
https://doi.org/10.1182/blood-2022-162739
Published: 2022
Journal Articles

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Sergiu Pasca, Saurav D. Haldar, Alexander J. Ambinder, Jonathan Webster, Tania Jain, William Brian Dalton, Gabrielle T. Prince, Gabriel Ghiaur, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Cory Schulz, Kristin Stokvis, Mark J. Levis, Richard J. Jones, Lukasz P. Gondek
Journal: Blood
Blood (2022) 140 (Supplement 1): 10629–10631.
https://doi.org/10.1182/blood-2022-169148
Published: 2022
Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Jonathan Allen Webster, Madison C. Reed, Hua-Ling Tsai, Alexander J. Ambinder, Tania Jain, Amy E. DeZern, Mark J. Levis, Margaret M. Showel, Gabrielle T. Prince, Christopher S. Hourigan, Javier Bolaños-Meade, Lukasz P. Gondek, Gabriel Ghiaur, William Brian Dalton, Suman Paul, Ephraim J. Fuchs, Christian B. Gocke, Abbas Abbas Ali, Douglas E. Gladstone, Carol Ann Huff, Ivan M. Borrello, Lode J. Swinnen, Nina D. Wagner-Johnston, Richard F. Ambinder, Leo Luznik, Ivana Gojo, B. Douglas Douglas Smith, Ravi Varadhan, Richard J. Jones, Philip H. Imus
Journal: Blood
Blood (2022) 140 (Supplement 1): 4813–4815.
https://doi.org/10.1182/blood-2022-171038
Published: 2022
Journal Articles

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Clinical Trials & Observations
Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Récher, Sung-Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee-Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramon Tiu, Mark J. Levis
Journal: Blood
Blood (2022) 139 (23): 3366–3375.
https://doi.org/10.1182/blood.2021011583
Published: 2022
Includes: Supplemental data